Ceftazidime-avibactam

DRUG14 trials

Sponsors

Pfizer, Temple University, National Institute of Allergy and Infectious Diseases (NIAID), Maimónides Biomedical Research Institute of Córdoba, University of Pittsburgh

Conditions

Acute-On-Chronic Liver FailureBacterial InfectionBacterial InfectionsBloodstream InfectionCarbapenem Resistant Bacterial InfectionCarbapenem-Resistant Enterobacteriaceae InfectionComplicated Intra-abdominal InfectionCritical Illness

Phase 1

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

CompletedNCT03978091

National Institute of Allergy and Infectious Diseases (NIAID)Bacterial Infection

Start: 2019-07-09End: 2020-11-23Updated: 2022-06-07

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

TerminatedNCT04040621

PfizerHospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

Start: 2020-06-15End: 2021-05-07Updated: 2022-09-09

Phase 3

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

CompletedNCT01726023

PfizerComplicated Intra-abdominal Infection

Start: 2013-01-31End: 2015-03-31Updated: 2017-09-06

Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections

TerminatedNCT05258851

King Faisal Specialist Hospital & Research CenterCarbapenem-Resistant Enterobacteriaceae Infection

Start: 2022-06-01End: 2024-01-28Updated: 2024-06-14

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

Not yet recruitingNCT06633718

Qilu Pharmaceutical Co., Ltd.Intra-abdominal Infections

Start: 2024-10-31End: 2027-05-30Target: 786Updated: 2024-10-09

A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

RecruitingNCT07327619

Qilu Pharmaceutical Co., Ltd.Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia

Start: 2026-01-22End: 2028-10-01Target: 420Updated: 2026-02-17

Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

RecruitingNCT07004049

National University of SingaporeBloodstream Infection, Carbapenem Resistant Bacterial Infection, Hospital Acquired Bacterial Pneumonia +2

Start: 2025-04-21End: 2028-12-31Target: 600Updated: 2025-06-04

Unknown Phase

Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

Temple UniversityBacterial Infections, Critical Illness, Renal Failure

Start: 2017-03-13End: 2020-10-21Target: 10Updated: 2019-04-10

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

CompletedNCT04167228

Maimónides Biomedical Research Institute of CórdobaCarbapenem-Resistant Enterobacteriaceae Infection

Start: 2019-10-01End: 2021-05-05Updated: 2021-07-20

Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF

CompletedNCT04358991

University of PittsburghBacterial Infections

Start: 2017-01-01End: 2019-12-31Updated: 2020-09-29

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

CompletedNCT04628572

PfizerGram Negative Infections

Start: 2021-01-29End: 2022-03-11Updated: 2024-08-14

Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients

Active, not recruitingNCT05413343

First Affiliated Hospital of Zhejiang UniversitySevere Sepsis

Start: 2021-06-01End: 2025-10-31Target: 30Updated: 2025-08-08

Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.

Not yet recruitingNCT06818565

Institute of Liver and Biliary Sciences, IndiaAcute-On-Chronic Liver Failure

Start: 2025-02-10End: 2026-12-31Target: 150Updated: 2025-02-10

Retrospective Study of Ceftazidime-Avibactam Treatment for Multidrug-Resistant Gram-Negative Bacterial Infections in King Chulalongkorn Memorial Hospital

Active, not recruitingTCTR20260114005

Kamonwan Jutivorakoolinfections caused by aerobic gram-negative pathogens. carbapenem-resistant Enterobacteriaceae, multi-drug resistant gram-negative bacteria, mortality rate, ceftazidime-avibactam

Start: 2023-06-01Target: 70Updated: 2026-03-30

Related Papers

Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme

Journal of Antimicrobial Chemotherapy2023-09-1316 citations

233. Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)

Open Forum Infectious Diseases2022-12-01

232. Population Pharmacokinetics (PopPK) of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)

Open Forum Infectious Diseases2022-12-01

Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.

2021-08-1021 citations

Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.

2020-08-0115 citations

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.

2018-09-0161 citations

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

International Journal of Antimicrobial Agents2017-03-29127 citations

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

Pharmacology Research & Perspectives2015-08-2542 citations